Analyzing Daré Bioscience (NASDAQ:DARE) & Newron Pharmaceuticals (OTCMKTS:NWPHF)

Newron Pharmaceuticals (OTCMKTS:NWPHF) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Valuation & Earnings

This table compares Newron Pharmaceuticals and Daré Bioscience’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Newron Pharmaceuticals	$6.82 million	23.82	-$17.63 million	N/A	N/A
Daré Bioscience	$2.82 million	10.13	-$30.16 million	($3.84)	-0.88

Newron Pharmaceuticals has higher revenue and earnings than Daré Bioscience.

Volatility and Risk

Newron Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Profitability

This table compares Newron Pharmaceuticals and Daré Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Newron Pharmaceuticals	N/A	N/A	N/A
Daré Bioscience	N/A	N/A	-139.90%

Analyst Ratings

This is a summary of recent ratings and price targets for Newron Pharmaceuticals and Daré Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Newron Pharmaceuticals	0	0	0	0	N/A
Daré Bioscience	0	1	2	0	2.67

Daré Bioscience has a consensus target price of $54.00, suggesting a potential upside of 1,492.92%. Given Daré Bioscience’s higher possible upside, analysts clearly believe Daré Bioscience is more favorable than Newron Pharmaceuticals.

Insider & Institutional Ownership

6.7% of Daré Bioscience shares are owned by institutional investors. 4.0% of Daré Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Daré Bioscience beats Newron Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

About Daré Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.